4,579 Shares in Regeneron Pharmaceuticals, Inc. $REGN Purchased by Daiichi Life Insurance Co. Ltd.

Daiichi Life Insurance Co. Ltd. purchased a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 2nd quarter, HoldingsChannel reports. The firm purchased 4,579 shares of the biopharmaceutical company’s stock, valued at approximately $2,855,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Insigneo Advisory Services LLC boosted its position in shares of Regeneron Pharmaceuticals by 3.0% during the 4th quarter. Insigneo Advisory Services LLC now owns 445 shares of the biopharmaceutical company’s stock valued at $343,000 after purchasing an additional 13 shares in the last quarter. Arjuna Capital raised its holdings in shares of Regeneron Pharmaceuticals by 3.2% in the 1st quarter. Arjuna Capital now owns 457 shares of the biopharmaceutical company’s stock worth $353,000 after purchasing an additional 14 shares in the last quarter. Guardian Wealth Advisors LLC NC raised its holdings in shares of Regeneron Pharmaceuticals by 3.3% in the 4th quarter. Guardian Wealth Advisors LLC NC now owns 443 shares of the biopharmaceutical company’s stock worth $342,000 after purchasing an additional 14 shares in the last quarter. TD Private Client Wealth LLC lifted its stake in Regeneron Pharmaceuticals by 9.7% during the fourth quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company’s stock valued at $130,000 after purchasing an additional 15 shares during the last quarter. Finally, MCF Advisors LLC lifted its stake in Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 15 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $834.04 on Monday. The business’s fifty day moving average price is $697.09 and its 200 day moving average price is $716.46. The firm has a market capitalization of $85.87 billion, a price-to-earnings ratio of 20.61, a PEG ratio of 1.42 and a beta of 0.21. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a 1-year low of $541.00 and a 1-year high of $847.00.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The firm had revenue of $4.29 billion during the quarter, compared to analyst estimates of $3.82 billion. During the same period last year, the company posted $12.81 EPS. The business’s quarterly revenue was up 16.7% compared to the same quarter last year. On average, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be given a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio is 9.29%.

Insider Buying and Selling

In related news, Director Kathryn Guarini sold 400 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $320,000.00. Following the completion of the sale, the director directly owned 603 shares in the company, valued at approximately $482,400. This trade represents a 39.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Arthur F. Ryan sold 200 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the transaction, the director directly owned 17,303 shares in the company, valued at $11,249,545.45. The trade was a 1.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 1,400 shares of company stock worth $1,090,030. 6.97% of the stock is owned by company insiders.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: The FDA approved Pasatru (garetosmab-grts) to reduce new heterotopic ossification lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). Approval was supported by the Phase 3 OPTIMA trial, which showed a 90% or greater reduction in new lesions at 56 weeks. As the first approved treatment demonstrating this benefit in FOP, Pasatru could expand Regeneron’s rare-disease portfolio and create a new revenue stream. Regeneron to challenge Ipsen as FDA clears bone disease drug
• Positive Sentiment: Regeneron is also pursuing growth in obesity treatment. An update on its Phase 2 olatorepatide study has drawn investor attention because the program could give the company exposure to the large and rapidly expanding obesity-drug market, although clinical and commercial risks remain. Regeneron’s Olatorepatide Trial Signals a Bid for Obesity Market Upside
• Neutral Sentiment: Multiple investor-law-firm notices announced a securities class action and a September 14, 2026 lead-plaintiff deadline. The claims relate to alleged disclosures about the Phase 3 Fianlimab-Libtayo melanoma trial; the notices themselves do not represent a new regulatory or operating development. Regeneron Investors Class Action Notice
• Negative Sentiment: The underlying litigation alleges that Regeneron misled investors about the viability and prospects of the Fianlimab-Libtayo trial, whose disappointing results reportedly caused a sharp share-price decline and an approximately $11 billion reduction in market value. Continued lawsuit announcements add reputational, legal-cost and potential financial-liability risks. Pomerantz Regeneron Investor Alert

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on REGN. Canaccord Genuity Group reduced their target price on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a report on Tuesday, May 19th. Sanford C. Bernstein raised Regeneron Pharmaceuticals to a “hold” rating in a report on Wednesday, July 29th. Morgan Stanley increased their price objective on Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the company an “equal weight” rating in a research report on Friday, July 31st. Piper Sandler reduced their price objective on Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating for the company in a research note on Thursday, July 9th. Finally, BMO Capital Markets decreased their target price on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating on the stock in a report on Monday, May 18th. Sixteen equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $801.70.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.